Skip to content
Our reporters bring you news and highlights from BIO’s in-person and virtual events.
Access to quality healthcare is a basic human right, regardless of socioeconomic status, race, ethnicity, gender, or geographic location. Despite this, disparities in healthcare […]
Dismantling disparities in healthcare through partnerships and policy Read More »
Antimicrobial resistance is one of the biggest global health challenges we face. Superbugs were linked to almost 5 million deaths worldwide in 2019, and
On AMR, ‘we need to be scared’ – and pass PASTEUR Read More »
Biopharma and biomanufacturing companies are working to address climate change, both in their own supply chains and more broadly, according to a June 7
How biopharma and biomanufacturing are changing the narrative on climate challenges Read More »
From vaccine-preventable viruses to antimicrobial-resistant infections, we “need to get ahead of disease,” said Emma Walmsley, CEO of GSK, at the 2023 Biotechnology Innovation
Getting ahead of disease – with technology and partnerships Read More »
The Inflation Reduction Act (IRA) will introduce arbitrary changes in drug development as pharma companies are forced to work with complex new regulations that
BIO panels break down IRA’s challenges for drug makers and patients Read More »
Healthcare on the African continent is changing. “At the current pace, the annual rate of cancer in Africa is projected to reach 1.4 million
How do we achieve the cancer moonshot in Africa? Read More »
Psychedelics have established themselves as a game changer in the drug development space in recent years. And it is not just scientists who are
Psychedelics ‘do things in the brain that nothing else does’ Read More »
Andrew Marshall’s life turned upside down when he was 16 and received an acute lymphoblastic leukemia diagnosis. As a budding musician, he would sit
The ultimate collaboration: Make-A-Wish Foundation and biotech Read More »
“We all just went through a pandemic together,” began Phyllis Arthur, Vice President of Infectious Disease & Emerging Science Policy at the Biotechnology Innovation
How can we increase routine adult vaccination? Read More »
The disease burden of RSV has been a tough problem for biotech R&D to solve for over 60 years. However, within the last year,
We’re conquering RSV for the young and old – but more innovation is needed Read More »
